Modeling pegcetacoplan treatment effect for atrophic age-related macular degeneration with AI-based progression prediction.

Irmela Mantel, Romina M Lasagni Vitar, Sandro De Zanet
{"title":"Modeling pegcetacoplan treatment effect for atrophic age-related macular degeneration with AI-based progression prediction.","authors":"Irmela Mantel, Romina M Lasagni Vitar, Sandro De Zanet","doi":"10.1186/s40942-025-00634-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>To illustrate the treatment effect of Pegcetacoplan for atrophy secondary to age-related macular degeneration (AMD), on an individualized topographic progression prediction basis, using a deep learning model.</p><p><strong>Methods: </strong>Patients (N = 99) with atrophy secondary to AMD with longitudinal optical coherence tomography (OCT) data were retrospectively analyzed. We used a previously published deep-learning-based atrophy progression prediction algorithm to predict the 2-year atrophy progression, including the topographic likelihood of future retinal pigment epithelial and outer retinal atrophy (RORA), according to the baseline OCT input. The algorithm output was a step-less individualized topographic modeling of the RORA growth, allowing for illustrating the progression line corresponding to an 80% growth compared to the natural course of 100% growth.</p><p><strong>Results: </strong>The treatment effect of Pegcetacoplan was illustrated as the line when 80% of the growth is reached in this continuous model. Besides the well-known variability of atrophy growth rate, our results showed unequal growth according to the fundus location. It became evident that this difference is of potential functional interest for patient outcomes.</p><p><strong>Conclusions: </strong>This model based on an 80% growth of RORA after two years illustrates the variable effect of treatment with Pegcetacoplan according to the individual situation, supporting personalized medical care.</p>","PeriodicalId":14289,"journal":{"name":"International Journal of Retina and Vitreous","volume":"11 1","pages":"14"},"PeriodicalIF":1.9000,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11806661/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Retina and Vitreous","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40942-025-00634-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: To illustrate the treatment effect of Pegcetacoplan for atrophy secondary to age-related macular degeneration (AMD), on an individualized topographic progression prediction basis, using a deep learning model.

Methods: Patients (N = 99) with atrophy secondary to AMD with longitudinal optical coherence tomography (OCT) data were retrospectively analyzed. We used a previously published deep-learning-based atrophy progression prediction algorithm to predict the 2-year atrophy progression, including the topographic likelihood of future retinal pigment epithelial and outer retinal atrophy (RORA), according to the baseline OCT input. The algorithm output was a step-less individualized topographic modeling of the RORA growth, allowing for illustrating the progression line corresponding to an 80% growth compared to the natural course of 100% growth.

Results: The treatment effect of Pegcetacoplan was illustrated as the line when 80% of the growth is reached in this continuous model. Besides the well-known variability of atrophy growth rate, our results showed unequal growth according to the fundus location. It became evident that this difference is of potential functional interest for patient outcomes.

Conclusions: This model based on an 80% growth of RORA after two years illustrates the variable effect of treatment with Pegcetacoplan according to the individual situation, supporting personalized medical care.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.50
自引率
4.30%
发文量
81
审稿时长
19 weeks
期刊介绍: International Journal of Retina and Vitreous focuses on the ophthalmic subspecialty of vitreoretinal disorders. The journal presents original articles on new approaches to diagnosis, outcomes of clinical trials, innovations in pharmacological therapy and surgical techniques, as well as basic science advances that impact clinical practice. Topical areas include, but are not limited to: -Imaging of the retina, choroid and vitreous -Innovations in optical coherence tomography (OCT) -Small-gauge vitrectomy, retinal detachment, chromovitrectomy -Electroretinography (ERG), microperimetry, other functional tests -Intraocular tumors -Retinal pharmacotherapy & drug delivery -Diabetic retinopathy & other vascular diseases -Age-related macular degeneration (AMD) & other macular entities
期刊最新文献
In-clinic vitreous biopsy peel pack technique. Systemic oxidative stress levels and their associations with the risk of neovascular age-related macular degeneration and treatment response. Modeling pegcetacoplan treatment effect for atrophic age-related macular degeneration with AI-based progression prediction. Tear glucose is associated with the presence and severity of diabetic retinopathy. Predictive value of different baseline optical coherence tomography biomarkers for visual acuity changes in neovascular age-related macular degeneration.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1